|
| 37509518 | MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation. | | 2023 |
| 35973817 | Translational significance of CDKN2A/B homozygous deletion in isocitrate dehydrogenase-mutant astrocytoma. | Neuro Oncol | 2023 |
| 36288512 | Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic <i>NF2</i> Mutations. | J Clin Oncol | 2023 |
| 37589827 | How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors. | | 2023 |
| 37828724 | Delivery versus potency in treating brain tumors: BI-907828, a MDM2-p53 antagonist with limited BBB penetration but significant in vivo efficacy in glioblastoma. | | 2023 |
| 37654190 | CHCHD2 mediates glioblastoma cell proliferation, mitochondrial metabolism, hypoxiaâ¿¿induced invasion and therapeutic resistance. | | 2023 |
| 37902550 | GTP signaling links metabolism, DNA repair, and responses to genotoxic stress. | | 2023 |
| 37638345 | Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients. | | 2023 |
| 37967136 | Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. | | 2023 |
| 37773633 | Magnetic resonance imaging of iron metabolism with T2* mapping predicts an enhanced clinical response to pharmacological ascorbate in patients with GBM. | | 2023 |
| 37090571 | GTP signaling links metabolism, DNA repair, and responses to genotoxic stress. | | 2023 |
| 37340056 | Blood-brain barrier disruption defines the extracellular metabolome of live human high-grade gliomas. | | 2023 |
| 37324218 | WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. | | 2023 |
| 37385378 | Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients. | | 2023 |
| 36865270 | Main Manuscript for Cell migration simulator-based biomarkers for glioblastoma. | bioRxiv | 2023 |
| 37370649 | Targeted c-Myc Inhibition and Systemic Temozolomide Therapy Extend Survival in Glioblastoma Xenografts. | | 2023 |
| 37239852 | Glycan Node Analysis Detects Varying Glycosaminoglycan Levels in Melanoma-Derived Extracellular Vesicles. | | 2023 |
| 36732634 | Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. | Nat Cancer | 2023 |
| 34887255 | Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor. | Drug Metabolism and Disposition | 2022 |
| 36109186 | Perivascular Stromal Cells Instruct Glioblastoma Invasion, Proliferation, and Therapeutic Response within an Engineered Brain Perivascular Niche Model. | Advanced Science | 2022 |
| 36104272 | Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer. | Clin Lung Cancer | 2022 |
| 35830573 | Phage Particles of Controlled Length and Genome for Targeted Glioblastoma Imaging and Therapeutic Delivery. | ACS Nano | 2022 |
| 35820185 | Characterization of Transgenic NSG-SGM3 Mouse Model of Precision Radiation-Induced Chronic Hyposalivation. | Radiat Res | 2022 |
| 35631512 | IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. | Pharmaceutics | 2022 |
| 35370138 | Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases. | Journal of Pharmacology and Experimental Therapeutics | 2022 |
| 36137710 | Central Nervous System Distribution of the Ataxia-Telangiectasia Mutated Kinase Inhibitor AZD1390: Implications for the Treatment of Brain Tumors. | Journal of Pharmacology and Experimental Therapeutics | 2022 |
| 36071925 | Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts. | Neuro-Oncology Advances | 2022 |
| 35486732 | Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. | Science advances | 2022 |
| 35795471 | Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma. | Neuro-Oncology Advances | 2022 |
| 36428586 | Modeling Therapy-Driven Evolution of Glioblastoma with Patient-Derived Xenografts. | Cancers (Basel) | 2022 |
| 35915159 | EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation. | Nat Cell Biol | 2022 |
| 34232318 | Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules. | Neuro Oncol | 2022 |
| 35040929 | massNet: integrated processing and classification of spatially resolved mass spectrometry data using deep learning for rapid tumor delineation. | Bioinformatics | 2022 |
| 35040235 | The influence of the blood-brain barrier in the treatment of brain tumours. | Journal of Internal Medicine | 2022 |
| 35231103 | RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma. | Neuro-Oncology | 2022 |
| 35191501 | Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition. | Molecular Cancer Research | 2022 |
| 34435883 | Matrix Hyaluronic Acid and Hypoxia Influence a CD133 Subset of Patient-Derived Glioblastoma Cells. | Tissue Engineering - Part A. | 2022 |
| 34383057 | Multimodal platform for assessing drug distribution and response in clinical trials. | Neuro Oncol | 2022 |
| 35134075 | The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma. | PLoS ONE | 2022 |
| 34818553 | Protein kinase C and SRC signaling define reciprocally related subgroups of glioblastoma with distinct therapeutic vulnerabilities. | Cell Reports | 2021 |
| 33707748 | EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma. | Oncogene | 2021 |
| 34016623 | Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks. | Cancer Res | 2021 |
| 34112916 | Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells. | Communications Biology | 2021 |
| 33736874 | Efflux Limits Tumor Drug Delivery Despite Disrupted BBB. | Trends in Pharmacological Sciences | 2021 |
| 34050676 | Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma. | Neuro Oncol | 2021 |
| 33785646 | Efficacy of Tesevatinib in -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. | Molecular Cancer Therapeutics | 2021 |
| 33524942 | Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma. | Neurosurgical Focus | 2021 |
| 34107029 | Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines. | Neuro-Oncology | 2021 |
| 33674749 | Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance. | Oncogene | 2021 |
| 33771703 | Initial Results of a Phase 2 Trial of F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma. | International Journal of Radiation Oncology Biology Physics | 2021 |